Vu H. Duong, Md
Assistant Professor
Medicine
University of Maryland Medical Center
United States of America
Biography
Dr. Duong joined the School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center as an Assistant Professor in 2012. His clinical focus is in acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, and bone marrow failure syndromes. His primary research interests are in developing and conducting clinical trials in patients with myelodysplastic syndromes and acute leukemias. He has been involved in several early-phase investigator-initiated clinical trials and has served as the local principal investigator for several industry-sponsored trials for patients with these diseases. In addition to clinical and research activities, he regularly serves as an attending physician on the inpatient leukemia service training fellows, internal medicine residents, and medical students.
Research Interest
Medicine
Publications
-
Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leukemia Research. 2013 March; 37(3):300-4, PMID: 23273539.
-
Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Therapeutic Advances in Hematology. 2012 April; 3(2): 105-16, PMID: 23556117.
-
Lancet JE, Duong VH, Winton EF, Stuart RK, Burton MK, Zhang S, Cubitt DL, Blaskovish MA, Wright JJ, Sebti SM, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical Cancer Research. 2011 March 1; 17(5):1140-6, PMID: 21233404.
